1 - 2 of 2
Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.
Dr. Mossé's research goal is to improve cure rates for the childhood cancer neuroblastoma by discovering the genetic basis of the disease and translating rational therapeutic opportunities to the clinic. She studies the contribution of DNA sequence variations and activation mutations of anaplastic lymphoma kinase (ALK) genes on the development and progression of both inherited and acquired forms of neuroblastoma.